On November 7, 2023 Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading commercial-stage innovative, global biopharmaceutical company dedicated to discovering, developing, and commercializing first-in-class and/or best-in-class medicines for hematology and oncology, reported that it will host its 2023 R&D Day on November 17, 2023, to update the medical and investor communities on the company’s progress with its R&D programs. The session will feature three KOL sessions, and discussions about the data of Antengene’s key drugs in clinical development, including ATG-031 (anti-CD24 monoclonal antibody), ATG-101 (PD-L1/4-1BB bispecific antibody), ATG-022 (Claudin 18.2 antibody-drug conjugate), ATG-037 (CD73 inhibitor), and ATG-008 (dual mTORC1/2 inhibitor); and updates on its proprietary R&D pipeline and upcoming development for 2024 (Press release, Antengene, NOV 7, 2023, View Source [SID1234637189]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Three guest experts will participate in the presentations and discussions at the event, they are: Dr. Adnan Khattak, M.D., Ph.D (One Clinical Research, Australia) who will discuss CD73 inhibitors; Dr. Anthony J. Olszanski, M.D., RPh(Fox Chase Cancer Center, the United States) who will discuss tumor immunotherapy, including targeting the PD-L1/4-1BB pathways; and Dr. Shehara Mendis, M.D., M.S. (Cabrini Health, Australia) who will discuss Claudin 18.2-targeting molecules.
Speakers from Antengene’s management team:
Jay Mei, M.D., Ph.D. – Founder, Chairman, and CEO
Amily Zhang, M.D. – Chief Medical Officer
Bo Shan, Ph.D. – Chief Scientific Officer
Godfrey Guo, M.D. – Executive Director, Clinical Development
Bing Hou, Ph.D. – Executive Director, Drug Discovery
A live question and answer session will follow the presentation.
The virtual event will be held in English at 8:30 AM, November 17, 2023, Eastern Time/ 9:30 PM, Beijing Time.
To attend the session, please register at View Source;tp_key=6683586ef4.
For participants in the Mainland of China, please register at View Source;tp_key=6683586ef4
A Hybrid Chinese session will also be held in-person at the Antengene Shanghai Office and virtually at 8:30 AM, November 17, 2023, Beijing Time.
To attend the event virtually, please register at View Source
For in-person attendance, please register at View Source or contact Antengene’s Investor Relations Team at [email protected].